ID   DERL-2
AC   CVCL_2016
SY   DERL2; DERL-NK2
DR   CLO; CLO_0037049
DR   BioSample; SAMN03473525
DR   cancercelllines; CVCL_2016
DR   Cell_Model_Passport; SIDM01509
DR   DepMap; ACH-001057
DR   DSMZ; ACC-531
DR   DSMZCellDive; ACC-531
DR   GEO; GSM1374460
DR   LINCS_LDP; LCL-1116
DR   Wikidata; Q54830978
RX   PubMed=10800166;
RX   PubMed=11587224;
RX   PubMed=28122867;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: 72 hours (PubMed=11587224); ~60 hours (DSMZ=ACC-531).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): DSMZ=ACC-531; PubMed=11587224
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 10,11
ST   D18S51: 14
ST   D19S433: 13,15
ST   D21S11: 29,30
ST   D2S1338: 23,24
ST   D3S1358: 14,15
ST   D5S818: 10,11
ST   D7S820: 11,12
ST   D8S1179: 13,14
ST   FGA: 20,22 (DSMZ=ACC-531)
ST   FGA: 21,22 (PubMed=11587224)
ST   Penta D: 11,13
ST   Penta E: 11,14
ST   TH01: 9
ST   TPOX: 8,11
ST   vWA: 17,19
DI   NCIt; C8459; Hepatosplenic T-cell lymphoma
DI   ORDO; Orphanet_86882; Hepatosplenic T-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_2017 ! DERL-7
SX   Male
AG   30Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 24
//
RX   PubMed=10800166;
RA   Camera A., Pezzullo L., Villa M.R., Luciano L., Pane F., Izzo B.,
RA   Boccuni P., Di Noto R., Del Vecchio L., Salvatore F., Rotoli B.;
RT   "Coexistence of two distinct cell populations (CD56(+)TcRgammadelta(+)
RT   and CD56(+)TcRgammadelta(-)) in a case of aggressive CD56(+)
RT   lymphoma/leukemia.";
RL   Haematologica 85:496-501(2000).
//
RX   PubMed=11587224; DOI=10.1038/sj.leu.2402239;
RA   Di Noto R., Pane F., Camera A., Luciano L., Barone M., Lo Pardo C.,
RA   Boccuni P., Intrieri M., Izzo B., Villa M.R., Macri M., Rotoli B.,
RA   Sacchetti L., Salvatore F., Del Vecchio L.;
RT   "Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/Tcry5+)
RT   and DERL-7 (CD56+/CD3-/TCRgammadelta-), derived from a single patient
RT   with CD56+ non-Hodgkin's lymphoma.";
RL   Leukemia 15:1641-1649(2001).
//
RX   PubMed=28122867; DOI=10.1158/2159-8290.CD-16-0330;
RA   McKinney M., Moffitt A.B., Gaulard P., Travert M., de Leval L.,
RA   Nicolae A., Raffeld M., Jaffe E.S., Pittaluga S., Xi L.-Q., Heavican T.,
RA   Iqbal J., Belhadj K., Delfau-Larue M.-H., Fataccioli V., Czader M.B.,
RA   Lossos I.S., Chapman-Fredricks J.R., Richards K.L., Fedoriw Y.,
RA   Ondrejka S.L., Hsi E.D., Low L., Weisenburger D.D., Chan W.C.,
RA   Mehta-Shah N., Horwitz S., Bernal-Mizrachi L., Flowers C.R.,
RA   Beaven A.W., Parihar M., Baseggio L., Parrens M., Moreau A.,
RA   Sujobert P., Pilichowska M., Evens A.M., Chadburn A., Au-Yeung R.K.-H.,
RA   Srivastava G., Choi W.W.L., Goodlad J.R., Aurer I., Basic-Kinda S.,
RA   Gascoyne R.D., Davis N.S., Li G.-J., Zhang J., Rajagopalan D., Reddy A.,
RA   Love C.L., Levy S., Zhuang Y., Datta J., Dunson D.B., Dave S.S.;
RT   "The genetic basis of hepatosplenic T-cell lymphoma.";
RL   Cancer Discov. 7:369-379(2017).
//